Exact Mass: 388.270443
Exact Mass Matches: 388.270443
Found 500 metabolites which its exact mass value is equals to given mass value 388.270443,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
2alpha-Methyl-17beta-[(tetrahydro-2H-pyran-2-yl)oxy]-5alpha-androstan-3-one
5,6-Dihydroxyprostaglandin F1a
Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs) and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes) and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signaling pathways. [HMDB] Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways.
Cavipetin C
Cavipetin C is found in mushrooms. Cavipetin C is a constituent of the edible mushroom Boletinus cavipes Constituent of the edible mushroom Boletinus cavipes. Cavipetin C is found in mushrooms.
Methyl 2-(10-heptadecenyl)-6-hydroxybenzoate
Methyl 2-(10-heptadecenyl)-6-hydroxybenzoate is found in fats and oils. Methyl 2-(10-heptadecenyl)-6-hydroxybenzoate is isolated from Ginkgo biloba (ginkgo). Isolated from Ginkgo biloba (ginkgo). Methyl 2-(10-heptadecenyl)-6-hydroxybenzoate is found in fats and oils.
7alpha-hydroxy-3-oxochol-4-en-24-oic Acid
7alpha-hydroxy-3-oxochol-4-en-24-oic Acid is also known as 3-oxo-7-Hydroxychol-4-enoic acid or 7-HOC acid. 7alpha-hydroxy-3-oxochol-4-en-24-oic Acid is considered to be practically insoluble (in water) and acidic. 7alpha-hydroxy-3-oxochol-4-en-24-oic Acid is a bile acid lipid molecule D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids 3-Oxo-7-hydroxychol-4-enoic acid is an endogenous metabolite. 3-Oxo-7-hydroxychol-4-enoic acid may be an important indicator of a poor prognosis in hepatobiliary disease[1].
MG(18:1(12Z)-2OH(9,10)/0:0/0:0)
MG(18:1(12Z)-2OH(9,10)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/18:1(12Z)-2OH(9,10)/0:0)
MG(0:0/18:1(12Z)-2OH(9,10)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
(ent-13E,14E)-15,16-Diacetoxy-7,13(16),14-labdatriene
(2E,6S)- 6-[(1R,3aS,5Z,9R,10Z,12aR)-1,2,3,3a,4,7,8,9,12,12a-Decahydro-9-hydroxy-3a,6,10-trimethyl-1-cyclopentacycloundecenyl]-2-methyl-2-heptenoic acid
18-(3-Methylbutanoyl)----7,15-Pimaradiene-2,18-diol|2alpha-hydroxy-19-isovaleroyl-9-epi-ent-pimara-7,15-diene
8beta-hydroxy-11alpha-tiglinoyloxy-sandaracopimar-15-ene
rel-(1R,5R)-2-(1-farnesyl-5-hydroxy-2-oxocyclohex-3-en-1-yl)-acetic acid methyl ester
(1R*,3S*,4R*,6S*)-9-(Acetoxy)-4-hydroxy-1-[(2Z)-2-methylbut-2-enoyloxy]bisabol-10(11)-ene|18-Acetoxy-15??-hydroxymansumbinone|28-acetoxy-15alpha-hydroxymansumbinone
(5S)-5-hydroxy-((10Z,13Z)-2-oxononadeca-10,13-dienyl)cyclohex-2-enone|(5S)-5-hydroxy-<(10Z,13Z)-2-oxononadeca-10,13-dienyl>cyclohex-2-enone
rel-(3S,1R,2S)-3-(1-farnesyl-2-hydroxy-4-oxocyclopentan-1-yl)-3-methoxypropanoic acid lactone
15alpha-isobutyroyloxykaur-16-en-19-oic acid|15alpha-isobutyryloxy-ent-kaurenic acid
butyl (2Z)-2-[(1R,4E,10E,14R)-4,10,14-trimethyl-6-oxo-15-oxabicyclo[12.1.0]pentadeca-4,10-dien-7-ylidene]propanoate|secosarcophinolide
1-O-acetyl-2-O-[(R)-3-hydroxyhexadecanoyl]-sn-glycerol
4,6,8,10,12,14,16-Heptamethyl-6,8,11-octadecatriene-3,5,13-trione
4-methoxy-6-ethoxy-2-[(8Z,11Z)-8,11,14-pentadecatriene]resorcinol
8beta-hydroxy-11alpha-senecioyloxy-sandaracopimar-15-ene
2alpha,19-diacetoxy-9-epi-ent-pimara-7,15-diene|Di-Ac-7,15-Pimaradiene-2,18-diol
Hexahydro-4-methoxy-4a-(3, 7, 11-trimethyl-2, 6, 10-dodecatrienyl)-cyclopenta[b]pyran-2, 6-dione, 9CI
(2-Acetyloxy-5,9-dimethyl-14-methylidene-5-tetracyclo[11.2.1.01,10.04,9]hexadecanyl)methyl acetate
Dimethyl-10-methoxy-9-hydroxy-octadecan-1,18-dioat
(1E,6E)-3-[(E)-acetoxymethylidene]-7-methyl-9-(2,6,6-trimethylcyclohex-2-enyl)nona-1,6-dienyl acetate
ent-14beta-tigloyloxy-19-norbeyer-15-en-19-hydroperoxide
6beta,18-diacetoxycassan-13,15-diene|6beta,18-dihydroxycassan-13,15-diene diacetate
Palmitoleoyl 3-carbacyclic Phosphatidic Acid
C20H37O5P (388.23784820000003)
3,6-Dioxo-5b-cholan-24-oic acid
BA-115-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-115-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-115-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-115-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-115-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
3,7-Dioxo-5b-cholan-24-oic acid
BA-116-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-116-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-116-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-116-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-116-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
3,12-Dioxo-5b-cholan-24-oic acid
BA-117-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-117-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-117-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-117-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-117-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
7,12-Dioxo-5b-cholan-24-oic acid
BA-118-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-118-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-118-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-118-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
3,6-Dioxo-5a-cholan-24-oic acid
BA-124-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-124-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-124-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-124-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
3,7-Dioxo-5a-cholan-24-oic acid
BA-125-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-125-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-125-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-125-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
3,12-Dioxo-5a-cholan-24-oic acid
BA-126-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-126-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-126-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-126-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-126-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
7,12-Dioxo-5a-cholan-24-oic acid
BA-127-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-127-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
methyl (4R)-4-((5R,9S,10S,12S,13R,17R)-12-hydroxy-10,13-dimethyl-2,5,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate
(R)-4-((7R,8S,9S,10R,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
(R)-4-((3R,5S,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoic acid
(R)-4-((5S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-3,6-dioxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
(R)-4-((5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3,7-dioxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
Pregn-4-en-20-one, 3b,17-dihydroxy-6a-methyl-, 17-acetate
Pregn-4-en-20-one, 17-(acetyloxy)-3-hydroxy-6-methyl-, (3a,6a)-
Gly Gly Lys Lys
C16H32N6O5 (388.24340620000004)
Gly Lys Gly Lys
C16H32N6O5 (388.24340620000004)
Gly Lys Lys Gly
C16H32N6O5 (388.24340620000004)
Lys Gly Gly Lys
C16H32N6O5 (388.24340620000004)
Lys Gly Lys Gly
C16H32N6O5 (388.24340620000004)
Lys Lys Gly Gly
C16H32N6O5 (388.24340620000004)
1α-hydroxy-25,26,27-trinorvitamin D3 24-carboxylic acid
1α-hydroxy-21-nor-20-oxavitamin D3 / 1α-hydroxy-21-nor-20-oxacholecalciferol
1α,25-dihydroxy-23,24-dinorvitamin D3 / 1α,25-dihydroxy-23,24-dinorcholecalciferol
1α,25-dihydroxy-26,27-dinorvitamin D3 / 1α,25-dihydroxy-26,27-dinorcholecalciferol
3α,12α-Dihydroxy-5β-chola-7,9(11)-dien-24-oic Acid
3α,12β-Dihydroxy-5β-chola-7,9(11)-dien-24-oic Acid
HU210
Cavipetin C
ascr#26
An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (14R)-14-hydroxypentadecanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.
oscr#26
An omega-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of 15-hydroxypentadecanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.
1alpha-hydroxy-25,26,27-trinorvitamin D3 24-carboxylic acid
1alpha-hydroxy-21-nor-20-oxavitamin D3 / 1alpha-hydroxy-21-nor-20-oxacholecalciferol
1alpha,25-dihydroxy-23,24-dinorvitamin D3
1alpha,25-dihydroxy-26,27-dinorvitamin D3
ST 24:3;O4
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids 3-Oxo-7-hydroxychol-4-enoic acid is an endogenous metabolite. 3-Oxo-7-hydroxychol-4-enoic acid may be an important indicator of a poor prognosis in hepatobiliary disease[1].
3-hydroxy-4R-methyl-2-(n-eicos-11-yn-19-enyl)but-2-enolide
3-[4-(N-Boc)piperazin-1-yl]phenylboronic acid pinacol ester
C21H33BN2O4 (388.25332480000003)
1,2-bis(ethenyl)benzene,buta-1,3-diene,methyl 2-methylprop-2-enoate,styrene
azepan-2-one,hexanedioic acid,2-piperazin-1-ylethanamine
TRANS-1-(4-PENTYLCYCLOHEXYL)-4-(2-(4-PROPOXYPHENYL)ETHYNYL)BENZENE
Galeterone
C26H32N2O (388.25145019999997)
D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor
8,8-bis(1H-indol-3-yl)-2,6-dimethyl-2-octanol
C26H32N2O (388.25145019999997)
4-(4-Boc-piperazino)phenylboronic Acid Pinacol Ester
C21H33BN2O4 (388.25332480000003)
2-[4-(N-Boc)piperazin-1-yl]phenylboronic acid pinacol ester
C21H33BN2O4 (388.25332480000003)
2,8-Diazaspiro[4.5]decane-2,8-dicarboxylic acid, 2-(1,1-dimethylethyl) 8-(phenylmethyl) ester
Dehydrodeoxycholic acid
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
(14R)-14-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]pentadecanoic acid
15-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]pentadecanoic acid
Anabiol
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid
1alpha-hydroxy-21-nor-20-oxavitamin D3/1alpha-hydroxy-21-nor-20-oxacholecalciferol
(4R)-4-[(7S,8S,9S,10R,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid
[3-Carboxy-2-(3-hydroxytetradecanoyloxy)propyl]-trimethylazanium
C21H42NO5+ (388.30628220000006)
[3-Carboxy-2-(2-hydroxytetradecanoyloxy)propyl]-trimethylazanium
C21H42NO5+ (388.30628220000006)
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-6-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(Z)-11-carboxy-10-hydroxyundec-9-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-5-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-4-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-9-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-8-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(Z)-11-carboxy-10-hydroxyundec-10-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-10-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-carboxy-2-[(E)-11-carboxy-3-hydroxyundec-7-enoyl]oxypropyl]-trimethylazanium
C19H34NO7+ (388.23351540000004)
[3-Carboxy-2-(12-carboxydodecanoyloxy)propyl]-trimethylazanium
(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2,6-diaminohexanoyl]amino]-4-oxobutanoyl]amino]hexanoic acid
C16H32N6O5 (388.24340620000004)
N-arachidonoyl-gamma-aminobutyrate
A monocarboxylic acid anion that is the conjugate base of N-arachidonoyl-gamma-aminobutyric acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
N-oleoyltaurine(1-)
C20H38NO4S- (388.25214080000006)
A fatty acid-taurine conjugate obtained by deprotonation of the sulfonate group of N-oleoyltaurine; major species at pH 7.3.
(13R)-13-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxotetradecanoic acid
14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxotetradecanoic acid
2-[(1S,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide
(1R,9S,10S,11S)-12-(cyclopropylmethyl)-N-[3-(dimethylamino)propyl]-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C21H32N4O3 (388.24742819999994)
N-[[(2R,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-methoxy-N-propan-2-ylacetamide
N-[[(2R,3S,4R)-1-acetyl-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-methoxy-N-propan-2-ylacetamide
(R)-4-((3R,5S,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-7-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoic acid
2-{6-Oxo-6-[4-(L-phenylalanyl)-1-piperazinyl]hexyl}guanidine
C20H32N6O2 (388.25866119999995)
methyl (4R)-4-((5R,9S,10S,12S,13R,17R)-12-hydroxy-10,13-dimethyl-2,5,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate
N-[[(2S,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-methoxy-N-propan-2-ylacetamide
N-[[(2S,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-methoxy-N-propan-2-ylacetamide
(1S,9R,10R,11R)-12-(cyclopropylmethyl)-N-[3-(dimethylamino)propyl]-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C21H32N4O3 (388.24742819999994)
(1R,4S,5R,9S,10S,13R,15S)-5,9-dimethyl-14-methylidene-15-(2-methylpropanoyloxy)tetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylic acid
[(2R)-3-carboxy-2-(12-carboxydodecanoyloxy)propyl]-trimethylazanium
(1S,2S,3E,7E,11E)-2,17-diacetoxycembra-3,7,11,15-tetraene
(1S,2R,3E,7E,11E)-2,17-diacetoxycembra-3,7,11,15-tetraene
(E,E)-(1R,2S,5R)-8-Phenylmenthyl 5-phenyl-2,4-pentadienoate
17alpha-Hydroxyprogesterone 3,20-bis(O-methyloxime)
2-(Trimethylsilyloxy)tetradecanoic acid trimethylsilyl ester
C20H44O3Si2 (388.28288339999995)
2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxyacetic acid
[1-carboxy-3-[3-[(E)-dec-4-enoyl]oxy-2-hydroxypropoxy]propyl]-trimethylazanium
7alpha-Hydroxy-3-oxochol-4-en-24-oic Acid
A 3-oxo Delta(4)-steroid that is 3-oxochol-4-en-24-oic acid carrying an additional 7alpha-hydroxy substituent. D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids 3-Oxo-7-hydroxychol-4-enoic acid is an endogenous metabolite. 3-Oxo-7-hydroxychol-4-enoic acid may be an important indicator of a poor prognosis in hepatobiliary disease[1].
3alpha-Hydroxy-12-oxo-5beta-chol-9(11)-en-24-oic Acid
3beta-Hydroxy-12-oxo-5beta-chol-9(11)-en-24-oic Acid
12alpha-Hydroxy-3-oxo-5beta-chol-9(11)-en-24-oic Acid
3alpha-Hydroxy-12-oxo-5beta-chol-8(14)-en-24-oic Acid
3alpha,12alpha-Dihydroxy-5beta-chola-7,14-dien-24-oic Acid
3alpha,12alpha-Dihydroxy-5beta-chola-8,14-dien-24-oic Acid
3alpha,12beta-Dihydroxy-5beta-chola-7,9(11)-dien-24-oic Acid
3alpha,12alpha-Dihydroxy-5beta-chola-7,9(11)-dien-24-oic Acid
[2-(acetyloxy)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methyl acetate
(1r,2s,3r,10e,14s)-2-acetyl-4-isopropyl-1,7,11-trimethyl-15-oxabicyclo[12.1.0]pentadeca-4,6,10-trien-3-yl acetate
14-(hydroxymethyl)-5,5,9-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-6-yl 2-methylbut-2-enoate
methyl 2-methoxy-6-[(8z,13s)-13-methylpentadec-8-en-1-yl]benzoate
(1r,4r,5r,9s,10s,13r,16s)-5-hydroperoxy-5,9,13-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-en-16-yl (2e)-2-methylbut-2-enoate
1-[(1r,4ar,7r,10as)-7-ethenyl-1,4a,7-trimethyl-3,4,5,6,8,9,10,10a-octahydro-2h-phenanthren-1-yl]methyl 3-methyl propanedioate
2-hydroxy-6-[(8z,11z,14r)-14-hydroxyheptadeca-8,11-dien-1-yl]benzoic acid
(1s,2s,3s,5r,6s,9s,13s,14r,17r,19r)-9-isopropyl-2,6,13,17-tetramethyl-18-oxapentacyclo[15.1.1.0²,¹⁴.0⁵,¹³.0⁶,¹⁰]nonadec-10-ene-3,19-diol
methyl 2-methoxy-6-(13-methylpentadec-8-en-1-yl)benzoate
[(1s,4ar,5s,8ar)-5-[(3r)-3-hydroxy-3-methylpent-4-en-1-yl]-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalen-1-yl]methyl (2e)-2-methylbut-2-enoate
1-methyl 3-{5,9,13-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-en-5-yl}methyl propanedioate
5b,8,8,11a,13a-pentamethyl-1h,3h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h,13bh-chryseno[1,2-c]furan-1,13-diol
13-(1-carboxyethyl)-2,5,10,14-tetramethyltetracyclo[7.7.0.0²,⁶.0¹⁰,¹⁴]hexadec-1(9)-ene-5-carboxylic acid
(2z)-3-(4-hydroxyphenyl)prop-2-en-1-yl hexadecanoate
4-ethoxy-6-methoxy-2-[(8z,11z)-pentadeca-8,11,14-trien-1-yl]benzene-1,3-diol
(1s,2s)-3-[(3s,3as,6s,7ar,10r,10ar,10bs)-3,6,7a,10-tetramethyl-1h,2h,3h,4h,5h,6h,8h,9h,10ah,10bh-cyclopenta[d]s-indacen-10-yl]-1-[(2s)-2-methyloxiran-2-yl]propane-1,2-diol
1-acetyl-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one
6-{9-hydroxy-3a,6,10-trimethyl-1h,2h,3h,4h,7h,8h,9h,12h,12ah-cyclopenta[11]annulen-1-yl}-2-methylhept-2-enoic acid
(1r,2r,4s,7s,8s,11s,12r,14s,17r,18s)-1-hydroxy-17-isopropyl-2,7,11,14-tetramethyl-3-oxapentacyclo[10.7.0.0²,⁴.0⁴,⁸.0¹⁴,¹⁸]nonadecan-16-one
(1r,5as,5br,7as,11as,11br,13r,13as,13bs)-5b,8,8,11a,13a-pentamethyl-1h,3h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h,13bh-chryseno[1,2-c]furan-1,13-diol
[(4as,5r,8as)-1-[(acetyloxy)methyl]-4a-methyl-6-methylidene-5-[(2e)-3-methylpenta-2,4-dien-1-yl]-hexahydro-2h-naphthalen-1-yl]methyl acetate
4-oxo-4-{[(1r,4s,5s,9s,10r,13s)-5,9,13-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-en-5-yl]methoxy}butanoic acid
(6e,8e,11e)-4,6,8,10,12,14,16-heptamethyloctadeca-6,8,11-triene-3,5,13-trione
18-acetoxy-15α-hydroxymansumbinone
{"Ingredient_id": "HBIN002084","Ingredient_name": "18-acetoxy-15\u03b1-hydroxymansumbinone","Alias": "NA","Ingredient_formula": "C24H36O4","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "229","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(1r*,3s*,4r*,6s*)-9-(acetoxy)-4-acetoxy-1-[(2z)-2-methylbut-2-enoyloxy]bisabol-10(11)-ene
{"Ingredient_id": "HBIN003106","Ingredient_name": "(1r*,3s*,4r*,6s*)-9-(acetoxy)-4-acetoxy-1-[(2z)-2-methylbut-2-enoyloxy]bisabol-10(11)-ene","Alias": "NA","Ingredient_formula": "C24H36O4","Ingredient_Smile": "CC(=O)OCC1(C2CCC3(C(C2(CCC1=O)C)CCC4C3(C(C=C4)O)C)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "119","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(1r*,3s*,4r*,6s*)-9-(acetoxy)-4-hydroxy-1-[(2z)-2-methylbut-2-enoyloxy]bisabol-10(11)-ene
{"Ingredient_id": "HBIN003108","Ingredient_name": "(1r*,3s*,4r*,6s*)-9-(acetoxy)-4-hydroxy-1-[(2z)-2-methylbut-2-enoyloxy]bisabol-10(11)-ene","Alias": "NA","Ingredient_formula": "C24H36O4","Ingredient_Smile": "CC(=O)OCC1(C2CCC3(C(C2(CCC1=O)C)CCC4C3(C(C=C4)O)C)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "230","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-n-tridecyl-5,7-dihydroxy-6,8-dimethyl chromone
{"Ingredient_id": "HBIN006157","Ingredient_name": "2-n-tridecyl-5,7-dihydroxy-6,8-dimethyl chromone","Alias": "2-n-tridecyl-5,7-dihydroxy-6,8-dimethyl chro-mone","Ingredient_formula": "C24H36O4","Ingredient_Smile": "Not Available","Ingredient_weight": "388.6","OB_score": "3.272540274","CAS_id": "NA","SymMap_id": "SMIT00865","TCMID_id": "21607","TCMSP_id": "MOL006581","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
bis(2-methylheptyl)phthalate
{"Ingredient_id": "HBIN018555","Ingredient_name": "bis(2-methylheptyl)phthalate","Alias": "NA","Ingredient_formula": "C24H36O4-2","Ingredient_Smile": "CCCCCC(C)CC1=C(C(=C(C=C1)C(=O)[O-])C(=O)[O-])CC(C)CCCCC","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "32954","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
1-{3,6,7a,10-tetramethyl-1h,2h,3h,4h,5h,6h,8h,9h,10ah,10bh-cyclopenta[d]s-indacen-10-yl}-2,4-dihydroxy-4-methylpentan-3-one
(3r,4ar,7ar)-3,4a-dimethyl-3-(10-phenyldecyl)-dihydro-4h-furo[3,2-c][1,2]dioxin-6-one
[(1r,4s,9s,10s,13s)-5-[(acetyloxy)methyl]-9,13-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-en-5-yl]methyl acetate
4-{[(1r,4ar,4br,10ar)-7-isopropyl-1,4a-dimethyl-2,3,4,4b,5,6,10,10a-octahydrophenanthren-1-yl]methoxy}-4-oxobutanoic acid
8-(acetyloxy)-2-isopropyl-5,13-dimethyl-9-methylidenecyclotetradeca-2,4,12-trien-1-yl acetate
[(1r,2s,4s,5s,9r,10s,13r)-2-(acetyloxy)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methyl acetate
(2e,6s)-6-[(1r,3as,9r,12ar)-9-hydroxy-3a,6,10-trimethyl-1h,2h,3h,4h,7h,8h,9h,12h,12ah-cyclopenta[11]annulen-1-yl]-2-methylhept-2-enoic acid
4-methoxy-4a-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-tetrahydro-3h-cyclopenta[b]pyran-2,6-dione
1-methyl 2,6,6-trimethyl-12-methylidenetetracyclo[11.2.1.0¹,¹⁰.0²,⁷]hexadecan-9-yl propanedioate
(4r,8e,11r,12e,14r,15r)-15-[(2r,3e)-hept-3-en-2-yl]-14-hydroxy-4,11-dimethyl-5-methylidene-1-oxacyclopentadeca-8,12-diene-2,10-dione
2-ethenyl-10a-hydroxy-2,4b,8,8-tetramethyl-decahydrophenanthren-4-yl 2-methylbut-2-enoate
7-hydroxy-1-(1-hydroxypropan-2-yl)-3a,6,9a,11a-tetramethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-6-carbaldehyde
4-{9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-2-hydroxypentanoic acid
(1r,3ar,5ar,6r,7r,9as,11ar)-7-hydroxy-1-[(2s)-1-hydroxypropan-2-yl]-3a,6,9a,11a-tetramethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-6-carbaldehyde
(2s)-pentan-2-yl 3-[(1s,2s,3r)-2-[2-(furan-3-yl)ethyl]-2,3-dimethyl-6-(propan-2-ylidene)cyclohexyl]propanoate
(1r,2r,4s,7s,8s,11r,12r,14s,17r,18s)-1-hydroxy-17-isopropyl-2,7,11,14-tetramethyl-3-oxapentacyclo[10.7.0.0²,⁴.0⁴,⁸.0¹⁴,¹⁸]nonadecan-16-one
1-methyl 3-[(1r,4s,5r,9s,10s,13s)-5,9,13-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-en-5-yl]methyl propanedioate
[(1r,2s,4s,5s,9r,10s,12r,13r,14s)-2-(acetyloxy)-5,9,13-trimethylpentacyclo[11.2.1.0¹,¹⁰.0⁴,⁹.0¹²,¹⁴]hexadecan-5-yl]methyl acetate
(2s,4r,4as,4bs,8as,10ar)-2-ethenyl-10a-hydroxy-2,4b,8,8-tetramethyl-decahydrophenanthren-4-yl (2e)-2-methylbut-2-enoate
(2e,6e,10e,14e)-3,7,11,15-tetramethyl-16-oxohexadeca-2,6,10,14-tetraen-1-yl (2z)-3-hydroxy-2-methylprop-2-enoate
6-(hydroxymethyl)-3-isopropyl-10,16a-dimethyl-14-methylidene-1h,2h,3h,3ah,8h,9h,12h,13h,15h,16h-cyclopenta[15]annulene-2,8-diol
4-oxo-4-{[(1r,4s,5s,9s,10s,13s)-5,9,13-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-en-5-yl]methoxy}butanoic acid
10'-(hydroxymethyl)-3,3',14'-trimethyl-5-(2-methylprop-1-en-1-yl)spiro[oxolane-2,6'-tricyclo[9.3.0.0³,⁷]tetradecan]-9'-en-14'-ol
4,4-dimethyl-1,3-bis(3-methylbut-2-en-1-yl)-5-(2-methylbutanoyl)-6-oxabicyclo[3.2.1]octane-7,8-dione
6-[(2e,4e,8e,10e)-6,8-dimethylpentadeca-2,4,8,10,14-pentaen-1-yl]-2,3,5-trimethyloxane-2,4-diol
(1r,4s,5r,9s,10r,12s,16r)-5,9-dimethyl-13-methylidene-16-[(2-methylpropanoyl)oxy]tetracyclo[10.2.2.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
3,7,11,15-tetramethyl-16-oxohexadeca-2,6,10,14-tetraen-1-yl 3-hydroxy-2-methylprop-2-enoate
butyl 2-{4,10,14-trimethyl-6-oxo-15-oxabicyclo[12.1.0]pentadeca-4,10-dien-7-ylidene}propanoate
5-(hydroxymethyl)-3-(icosa-11,13-diyn-1-yl)oxolan-2-one
{1-[(acetyloxy)methyl]-4a-methyl-6-methylidene-5-(3-methylpenta-2,4-dien-1-yl)-hexahydro-2h-naphthalen-1-yl}methyl acetate
2-[5-(acetyloxy)-6,10-dimethyltricyclo[5.3.0.0²,⁶]decan-3-yl]-6-methylhepta-1,5-dien-4-yl acetate
[(1s,4s,9s,10r,13r)-5-[(acetyloxy)methyl]-9-methyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methyl acetate
(1r,4s,7e,9s,10s,13s)-5,5,9,13-tetramethyl-7-(phenylmethylidene)tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-ene-6,12-dione
(1s,2s)-2-hydroxy-1-tetradecylpropane-1,2,3-tricarboxylic acid
(2e)-3-(3,4-dimethoxyphenyl)-n-{4-[n'-(3-methylbut-2-en-1-yl)carbamimidamido]butyl}prop-2-enimidic acid
C21H32N4O3 (388.24742819999994)
(1r,3r,4s,4ar,8ar)-4-[(3s)-3-hydroxy-3-methylpent-4-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl (2z)-2-methylbut-2-enoate
(1s,4s,6r,9s,10s,13r,14r)-14-hydroxy-5,5,9,14-tetramethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-6-yl (2z)-2-methylbut-2-enoate
(2r)-pentan-2-yl 3-[(1s,2s,3r)-2-[2-(furan-3-yl)ethyl]-2,3-dimethyl-6-(propan-2-ylidene)cyclohexyl]propanoate
(1s,3s,5s)-4,4-dimethyl-1,3-bis(3-methylbut-2-en-1-yl)-5-[(2s)-2-methylbutanoyl]-6-oxabicyclo[3.2.1]octane-7,8-dione
(4r)-4-[(1r,3as,3bs,9ar,9bs,11ar)-9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-hydroxypentanoic acid
(5r)-1-methoxy-1-oxodecan-5-yl (3r,5r)-3,5-dihydroxydecanoate
[(1s,4s,4ar,8as)-4-(acetyloxy)-5,5,8a-trimethyl-1-[(2e)-3-methylpenta-2,4-dien-1-yl]-1,4,4a,6,7,8-hexahydronaphthalen-2-yl]methyl acetate
(2s,5r,6r,10r,13r,14r)-13-[(1s)-1-carboxyethyl]-2,5,10,14-tetramethyltetracyclo[7.7.0.0²,⁶.0¹⁰,¹⁴]hexadec-1(9)-ene-5-carboxylic acid
5,9-dimethyl-13-methylidene-16-[(2-methylpropanoyl)oxy]tetracyclo[10.2.2.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
(2s,4r,4as,4bs,8as,10ar)-2-ethenyl-10a-hydroxy-2,4b,8,8-tetramethyl-decahydrophenanthren-4-yl 3-methylbut-2-enoate
[2-(acetyloxy)-5,9,13-trimethylpentacyclo[11.2.1.0¹,¹⁰.0⁴,⁹.0¹²,¹⁴]hexadecan-5-yl]methyl acetate
16-isopropyl-1,5,9,13-tetramethyl-6-oxapentacyclo[10.7.0.0²,⁹.0⁵,⁷.0¹³,¹⁷]nonadec-17-ene-8,10-diol
(2e)-5-[3-hydroxy-5,8a-dimethyl-2-methylidene-5-(4-methylpent-3-en-1-yl)-hexahydro-1h-naphthalen-1-yl]-3-methylpent-2-enoic acid
(1r,3ar,5ar,6r,7s,9as,11ar)-7-hydroxy-1-[(2s)-1-hydroxypropan-2-yl]-3a,6,9a,11a-tetramethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-6-carbaldehyde
methyl 2-[(1s,5s)-5-hydroxy-2-oxo-1-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]cyclohex-3-en-1-yl]acetate
(1s,2r,6s,7s,8s,9s,11r,12s,15s)-15-isopropyl-1,8,12-trimethyl-5-methylidenetetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadec-16-ene-6,7,9-triol
[(1s,2s,4r,5s,9r,10r,13s)-2-(acetyloxy)-5,9,13-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-en-5-yl]methyl acetate
[4-(acetyloxy)-5,5,8a-trimethyl-1-(3-methylpenta-2,4-dien-1-yl)-1,4,4a,6,7,8-hexahydronaphthalen-2-yl]methyl acetate
[10-(acetyloxy)-7-ethenyl-1,4a,8-trimethyl-2,3,4,4b,5,6,8a,9,10,10a-decahydrophenanthren-1-yl]methyl acetate
(2s)-1-[(3s,3as,6s,7ar,10r,10ar,10bs)-3,6,7a,10-tetramethyl-1h,2h,3h,4h,5h,6h,8h,9h,10ah,10bh-cyclopenta[d]s-indacen-10-yl]-2,4-dihydroxy-4-methylpentan-3-one
(4s)-2-[(2r,3r,6r,10r)-5-(acetyloxy)-6,10-dimethyltricyclo[5.3.0.0²,⁶]decan-3-yl]-6-methylhepta-1,5-dien-4-yl acetate
3-{3,6,7a,10-tetramethyl-1h,2h,3h,4h,5h,6h,8h,9h,10ah,10bh-cyclopenta[d]s-indacen-10-yl}-1-(2-methyloxiran-2-yl)propane-1,2-diol
2-hydroxy-1-tetradecylpropane-1,2,3-tricarboxylic acid
(5s)-5-methyl-3-{14-[(5s)-5-methyl-2-oxo-5h-furan-3-yl]tetradec-7-en-1-yl}-5h-furan-2-one
2-[2-(acetyloxy)ethenyl]-6-methyl-8-(2,6,6-trimethylcyclohex-2-en-1-yl)octa-1,5-dien-1-yl acetate
(1r,2r,5r,10r,12r)-13-[(4r,5s)-4,5-dimethyl-1,3-dioxolan-2-yl]-8-isopropyl-2,5-dimethyl-15-oxatetracyclo[10.2.1.0²,¹⁰.0⁵,⁹]pentadeca-8,13-dien-1-ol
2-ethenyl-10a-hydroxy-2,4b,8,8-tetramethyl-decahydrophenanthren-4-yl 3-methylbut-2-enoate
1-methyl (1s,2s,7s,9s,10s,13s)-2,6,6-trimethyl-12-methylidenetetracyclo[11.2.1.0¹,¹⁰.0²,⁷]hexadecan-9-yl propanedioate
5-hydroperoxy-5,9,13-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-en-16-yl 2-methylbut-2-enoate
(1r,2r,3as,3bs,7r,9ar,9br,11ar)-1-acetyl-2,7-dihydroxy-3a,6,6,9b,11a-pentamethyl-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-10-one
[(1z,3z,5r,7e,11e)-5-(acetyloxy)-4-isopropyl-7,11-dimethylcyclotetradeca-1,3,7,11-tetraen-1-yl]methyl acetate
5-(furan-3-yl)-2-{[1-(hydroxymethyl)-1,4a-dimethyl-7-methylidene-octahydrobenzo[7]annulen-6-yl]methyl}pentan-1-ol
2-[2-(1,2,4a-trimethyl-5-methylidene-3,4,8,8a-tetrahydro-2h-naphthalen-1-yl)ethyl]-4-(acetyloxy)but-2-en-1-yl acetate
2-[(8z,11z)-heptadeca-8,11-dien-1-yl]-4,6-dihydroxybenzoic acid
(1e,5e,9e)-2-[(1e)-2-(acetyloxy)ethenyl]-6,10,14-trimethylpentadeca-1,5,9,13-tetraen-1-yl acetate
butyl 2-[(1r,4e,7z,10e,14r)-4,10,14-trimethyl-6-oxo-15-oxabicyclo[12.1.0]pentadeca-4,10-dien-7-ylidene]propanoate
(2r,4r)-4-[(1r,3as,3bs,9ar,9bs,11ar)-9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-hydroxypentanoic acid
6-[2-(but-2-en-2-yl)-6-hydroxy-5-methoxy-1a,6-dimethyl-octahydronaphtho[1,2-b]oxiren-3-yl]-3-methylhexa-3,5-dien-2-one
9-isopropyl-2,6,13,17-tetramethyl-18-oxapentacyclo[15.1.1.0²,¹⁴.0⁵,¹³.0⁶,¹⁰]nonadec-10-ene-3,19-diol
2-(heptadeca-8,11-dien-1-yl)-4,6-dihydroxybenzoic acid
(3s,4ar,7ar)-3,4a-dimethyl-3-(10-phenyldecyl)-dihydro-4h-furo[3,2-c][1,2]dioxin-6-one
2,3-dimethoxy-5-methyl-6-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]benzene-1,4-diol
(1s,4s,6r,9s,10s,13r,14s)-14-(hydroxymethyl)-5,5,9-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-6-yl (2z)-2-methylbut-2-enoate
[2-(acetyloxy)-5,9,13-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-en-5-yl]methyl acetate
(1s,2r)-2-hydroxy-1-tetradecylpropane-1,2,3-tricarboxylic acid
(1e,5e)-2-[(1e)-2-(acetyloxy)ethenyl]-6-methyl-8-[(1s)-2,6,6-trimethylcyclohex-2-en-1-yl]octa-1,5-dien-1-yl acetate
(1s,2z,4e,8r,12e)-8-(acetyloxy)-2-isopropyl-5,13-dimethyl-9-methylidenecyclotetradeca-2,4,12-trien-1-yl acetate
(1r,2s,3r,4z,6e,10e,14s)-2-acetyl-4-isopropyl-1,7,11-trimethyl-15-oxabicyclo[12.1.0]pentadeca-4,6,10-trien-3-yl acetate
13-(4,5-dimethyl-1,3-dioxolan-2-yl)-8-isopropyl-2,5-dimethyl-15-oxatetracyclo[10.2.1.0²,¹⁰.0⁵,⁹]pentadeca-8,13-dien-1-ol
pentan-2-yl 3-{2-[2-(furan-3-yl)ethyl]-2,3-dimethyl-6-(propan-2-ylidene)cyclohexyl}propanoate
(2s)-2-amino-n,3-dihydroxy-n-(10-hydroxy-3-oxoheptadecyl)propanamide
C20H40N2O5 (388.29370700000004)